BioNTech Shares Under Pressure as FDA Memo Sparks Sector-Wide Selloff
Published on 12/02/2025 at 09:05 | Redaktion boerse-global.de
December has opened with a jolt for BioNTech and its investors. A strategic pivot toward oncology and a critical acquisition are now overshadowed by regulatory tremors emanating from the United States. An internal memo from the U.S. Food and Drug Administration (FDA) has sent shockwaves through the biotechnology sector, raising urgent questions about the company’s near-term trajectory amid mounting challenges.
The immediate catalyst for a sharp sector decline was a document from Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER). The memo discusses a potential link between COVID-19 vaccines and fatal myocarditis, or heart inflammation, in children. It cites at least ten such Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
